Exelixis, Inc. $EXEL Shares Sold by Jupiter Asset Management Ltd.

Key Points

• Jupiter Asset Management Ltd. trimmed its Exelixis stake by 3.5% in the fourth quarter, selling 74,235 shares and still holding about 2.04 million shares valued at roughly $89.3 million.
• Exelixis reported better-than-expected first-quarter results, with EPS of $0.87 versus $0.75 expected and revenue of $610.81 million, up 10% year over year.
• Despite recent analyst and institutional activity, insider selling has been notable, including sales by a director and the CFO, while the stock continues to trade near its 12-month high.

Jupiter Asset Management Ltd. lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 3.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,037,698 shares of the biotechnology company's stock after selling 74,235 shares during the period. Jupiter Asset Management Ltd. owned approximately 0.76% of Exelixis worth $89,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in EXEL. Kestra Investment Management LLC increased its stake in Exelixis by 3.5% during the fourth quarter. Kestra Investment Management LLC now owns 28,653 shares of the biotechnology company's stock worth $1,256,000 after acquiring an additional 982 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Exelixis by 228.4% in the 4th quarter. Fisher Asset Management LLC now owns 153,724 shares of the biotechnology company's stock valued at $6,738,000 after purchasing an additional 106,912 shares during the last quarter. Westover Capital Advisors LLC grew its holdings in shares of Exelixis by 12.2% during the 4th quarter. Westover Capital Advisors LLC now owns 86,427 shares of the biotechnology company's stock worth $3,788,000 after purchasing an additional 9,392 shares during the period. Clearstead Advisors LLC increased its position in shares of Exelixis by 196.2% during the 4th quarter. Clearstead Advisors LLC now owns 9,619 shares of the biotechnology company's stock worth $422,000 after purchasing an additional 6,371 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in Exelixis by 166.6% in the 4th quarter. Hantz Financial Services Inc. now owns 7,032 shares of the biotechnology company's stock valued at $308,000 after buying an additional 4,394 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, reinforcing expectations that the company can continue delivering solid profitability.
• Positive Sentiment: Exelixis is set to participate in upcoming June investor conferences, which can help keep attention on the stock and provide new updates on pipeline and commercial progress. Article Title
• Positive Sentiment: A recent article argued that profitable, cash-generative biotech names like Exelixis may benefit as investors rotate away from expensive growth stocks and toward defensive healthcare ideas. Article Title
• Positive Sentiment: At the company’s annual meeting, investors backed the board, equity plan, and executive pay, signaling governance support and reducing uncertainty. Article Title
• Neutral Sentiment: Exelixis presented at Bernstein’s Strategic Decisions Conference, which keeps the company visible to institutional investors but did not include any major new operating update. Article Title
• Neutral Sentiment: A short-interest report showed essentially no short interest in Exelixis, suggesting limited bearish positioning but not a meaningful catalyst on its own.
• Negative Sentiment: EVP Dana Aftab sold 43,451 shares at an average price of $50.35, a disclosed insider sale that can weigh on sentiment even though the executive still holds a large position. Article Title

Exelixis Price Performance

EXEL opened at $51.45 on Friday. The business has a fifty day moving average price of $45.83 and a 200 day moving average price of $44.18. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $52.96. The stock has a market capitalization of $12.93 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.06 and a beta of 0.38.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to analysts' expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.55 EPS. On average, research analysts anticipate that Exelixis, Inc. will post 3.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on EXEL. Royal Bank Of Canada lowered their target price on shares of Exelixis from $46.00 to $43.00 and set a "sector perform" rating for the company in a research note on Monday, March 2nd. Wall Street Zen upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 9th. Wells Fargo & Company increased their price objective on shares of Exelixis from $35.00 to $40.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 6th. Morgan Stanley lifted their target price on shares of Exelixis from $49.00 to $50.00 and gave the company an "equal weight" rating in a report on Wednesday, May 6th. Finally, Stifel Nicolaus upped their price target on Exelixis from $44.00 to $47.00 and gave the stock a "hold" rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $47.35.

Insider Buying and Selling at Exelixis

In related news, Director George Poste sold 60,000 shares of the business's stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $45.71, for a total transaction of $2,742,600.00. Following the completion of the transaction, the director owned 118,832 shares in the company, valued at approximately $5,431,810.72. The trade was a 33.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 34,901 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the transaction, the chief financial officer directly owned 952,317 shares in the company, valued at $47,615,850. This trade represents a 3.54% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 205,433 shares of company stock worth $9,930,259. 2.60% of the stock is currently owned by company insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.